Cargando…

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations

BACKGROUND: From earlier studies it is known that the APOE ε2/ε3/ε4 polymorphism modulates the concentrations of cerebrospinal fluid (CSF) beta-amyloid(1–42) (Aβ42) in patients with cognitive decline due to Alzheimer’s disease (AD), as well as in cognitively healthy controls. Here, in a large cohort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lautner, Ronald, Insel, Philip S., Skillbäck, Tobias, Olsson, Bob, Landén, Mikael, Frisoni, Giovanni B., Herukka, Sanna-Kaisa, Hampel, Harald, Wallin, Anders, Minthon, Lennart, Hansson, Oskar, Blennow, Kaj, Mattsson, Niklas, Zetterberg, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654097/ https://www.ncbi.nlm.nih.gov/pubmed/29061195 http://dx.doi.org/10.1186/s13195-017-0313-3

Ejemplares similares

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
por: Mattsson, Niklas, et al.
Publicado: (2016)

CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4
por: Andreasson, U, et al.
Publicado: (2014)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease
por: Voevodskaya, Olga, et al.
Publicado: (2016)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
por: Cullen, Nicholas C., et al.
Publicado: (2020)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease
por: Andersson, Carl-Henrik, et al.
Publicado: (2016)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
por: Brinkmalm, Ann, et al.
Publicado: (2014)

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
por: van Westen, Danielle, et al.
Publicado: (2016)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Decreased plasma C‐reactive protein levels in APOE ε4 allele carriers
por: Martiskainen, Henna, et al.
Publicado: (2018)

Biomarkers for Microglial Activation in Alzheimer's Disease
por: Lautner, Ronald, et al.
Publicado: (2011)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease
por: Skillbäck, Tobias, et al.
Publicado: (2017)

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
por: Sjölander, Annica, et al.
Publicado: (2010)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease
por: Zetterberg, Madeleine, et al.
Publicado: (2010)

Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ϵ4 carriers
por: Spotorno, Nicola, et al.
Publicado: (2022)

Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information
por: Insel, Philip S., et al.
Publicado: (2016)

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
por: Zetterberg, Henrik, et al.
Publicado: (2010)

APOE-ε4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks
por: Cacciaglia, Raffaele, et al.
Publicado: (2020)

Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease
por: Johansson, Per, et al.
Publicado: (2013)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study
por: Mattsson, Niklas, et al.
Publicado: (2018)

Ubiquitin Carboxyl-Terminal Esterase LI (UCHLI) SI8Y Polymorphism in Patients with Cataracts
por: Rudolph, Thiemo, et al.
Publicado: (2011)

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype
por: Janelidze, Shorena, et al.
Publicado: (2017)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Fluid biomarkers in Alzheimer’s disease – current concepts
por: Rosén, Christoffer, et al.
Publicado: (2013)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5mjck0ebbl1qguu4b5580m86f4